Why the study?
Calcific aortic stenosis lacks effective medical therapy, and it remains to be shown whether augmentation of the CNP pathway is a viable therapeutic strategy.
Is the CNP/NPR-B/cGMP axis a viable therapeutic target for calcific aortic stenosis?
Is the CNP/NPR-B/cGMP axis a viable therapeutic target for calcific aortic stenosis?
The CNP/NPR-B/cGMP signaling pathway regulates valve matrix biology and is downregulated in severe CAS, highlighting it as a potential therapeutic target.
Answers are grounded in this paper and cite their sources.
CNP/NPR-B signaling protects against CAS in animal models; leaves open whether this axis offers a viable human therapeutic target.
C alcific aortic stenosis (CAS) is a disease for which there is no effective medical therapy.The natriuretic peptide system (NPS) is well characterized in the context of heart failure, but it is increasingly clear that the NPS plays a role in the development of CAS.The overwhelming majority of clinical data regarding the NPS in CAS focuses on natriuretic peptides in risk stratification, but there are human and experimental data suggesting C-type natriuretic peptide (CNP) / natriuretic peptide receptor (NPR) B (also known as guanylate cyclase B or GC-B) signaling plays a direct role in the development of CAS (Figure 1).However, it remains to be shown that augmentation of the CNP pathway is a viable therapeutic strategy in CAS.CNP REGULATES EXTRACELLULAR MATRIX AND FIBROSIS CNP has been shown to be the most potent antifibrotic natriuretic peptide compared to atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP).CNP also exerts direct effects on fibroblast, reducing fibroblast proliferation and collagen production in vitro, possibly via cyclic guanosine monophosphate (cGMP)-dependent and cGMP-independent mechanisms.The unique properties of CNP on regulating fibroblasts and extracellular matrix suggest that CNP may play a role in regulating matrix biology in aortic valve (AV) tissue.DEFICIENCY OF CNP IN CAS Initial reports identifying a possible causal role for the NPS in CAS come from basic studies in animal models.Using microarray analysis to examine gene expression in healthy porcine AVs, it was reported that NPPC (the gene encoding CNP) was more highly expressed on the disease-protected ventricular side of the valve (1).Immunostaining confirmed expression of CNP in freshly isolated valvular intestinal cells (VICs).In the fibrosa of sclerotic AVs there was also evidence of increased VIC myofibroblast differentiation (elevated smooth muscle alpha-actin immunostaining) associated with reduced or absent CNP (2).The first report of NPS expression in human AV tissue was from Finland in 2007 (3).In severe CAS there was significantly reduced expression of NPPC, FURIN (the gene encoding furin, which converts proCNP to biologically active CNP), NPR1 (the gene encoding NPR-A, the receptor for ANP and BNP) and NPR2 (the gene encoding NPR-B, the receptor for CNP), without changes in NPPA or NPPB (the genes encoding ANP and BNP, respectively).
No takes yet. Share an insight, caveat, or question.
Armstrong et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: